1. thisiswheremymon
2. maclia
3. asal3986
4. hoffman4568john
5. sanderfilon
1.thisiswheremymon 01/25/2018
Biogen is acquiring KPT-350 and other assets targeting certain neurological conditions, including amyotrophi…
2.maclia 01/25/2018
Misses EPS estimates by $0.19. Beats on revenues.
3.maclia 01/26/2018
Bigger than most are thinking
4.maclia 04/22/2018
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
5.hoffman4568john 02/07/2018
Reports top-line results from phase 2b study of Natalizumab.
6.maclia 01/26/2018
Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment of Neurological and Neurodegenerative Conditions
7.thisiswheremymon 01/24/2018
Canaccord Genuity raises PT to $350 from $340
8.asal3986 04/11/2018
Mizuho Securities sets PT at $433
9.maclia 03/12/2018
Reports new interim Phase 2 results from NURTURE
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW